Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 17/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14130781 | 0.95 | P2RY12 (0.46) | P2RY12MEN1HTR6 | |
| SCHEMBL14130667 | 0.94 | P2RY12 (0.45) | P2RY12MEN1HTR6 | |
| SCHEMBL4723745 | 0.91 | P2RY12 (0.51) | P2RY12MEN1HTR6 | |
| SCHEMBL4723435 | 0.91 | P2RY12 (0.50) | P2RY12MEN1HTR6 | |
| SCHEMBL4724405 | 0.89 | P2RY12 (0.49) | P2RY12MEN1HTR6 | |
| SCHEMBL14130795 | 0.89 | P2RY12 (0.50) | P2RY12MEN1HTR6 | |
| SCHEMBL4764223 | 0.89 | P2RY12 (0.49) | P2RY12MEN1HTR6 | |
| SCHEMBL4723264 | 0.89 | P2RY12 (0.49) | P2RY12MEN1HTR6 | |
| SCHEMBL4723826 | 0.86 | P2RY12 (0.49) | P2RY12MEN1HTR6 | |
| SCHEMBL14130782 | 0.85 | P2RY12 (0.46) | P2RY12MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | P2RY12 17/4885MEN1 4451/4885HTR6 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.